"We’re excited to continue growing our business by focussing on building key strengths"

An update from Medcan

This article is from Unspecified for Health Care, Medical & Biotech

"About Medcan 

In 2016, Medcan was founded to bring safe, effective treatment to millions of Australians suffering with lifealtering conditions from chronic pain to epilepsy. Since then, we’ve relentlessly executed on our mission to provide reliable access to patient-specific Medicinal Cannabis products and have grown to become industry-leading innovators along the way.

Our products & patients 

Medcan grows, manufactures, exports, and distributes a wide range of medicinal cannabis products. Our products are currently prescribed by specifically trained doctors under the TGA’s Special Access Scheme B to thousands of Australians each month, giving them relief, recovery, and hope (see Channel 9 video).

Our businesses

Medcan has built a strategic suite of complementary businesses. Each valuable in their own right, the combination of these businesses results in a highly accretive, fully vertically integrated business model.

Our trajectory 

We’re excited to continue growing our business by focussing on building key strengths.

FY2021 Highlights

  • First Australian Medicinal Cannabis company to pay a dividend 
  • 454% shareholder uplift since seed round 
  • 658% revenue increase FY2020 to FY2021

Our FY22 targets

  • 6,000kg/year manufacturing capacity
  • 10k new patients
  • 60k+ unit sales
  • $3.4m+ projected EBITDA
  • 20% projected dividend."

About Medcan

Founded in Australia in 2016, Medcan is a medicinal cannabis cultivation, production, research, manufacturing, import, export and distribution company aiming to apply state of the art technologies to produce and distribute GMP medicinal cannabis products to domestic and international markets. Medcan has secured all the licences required to execute its business model including all Office Drug Control (ODC), State (QLD Health), Biosecurity (Department of Agriculture and Water Resources - DAWR) licences. Contact us to find out more.  

About BlueMount Capital

BlueMount Capital is an ASIC licensed capital markets group with offices in Sydney, Brisbane, Melbourne, Perth, Los Angeles and Beijing. We have global connections to capital market groups through our colleagues in the USA/UK/Europe and India.  We are also a member of Orion International Advisors (formerly IAIB), an exclusive network of investment bankers from America, UK, Europe and Asia.

Our team are experts in helping you capitalize on changing market conditions. Our directors have extensive experience assisting private and public companies, and sophisticated investors.

If you would like more information about Medcan, please email brisbane@bluemountcapital.com or phone +61 7 3160 2840.

Related Attachments

February 24th, 2022

Medcan | Update | 24 February 2022 ( 153.72 KB )